January 31, 2017: Diabetic Ketoacidosis with SGLT2 Inhibitors
Diabetic ketoacidosis (DKA) is a rare medical emergency resulting from insulin deficiency, making it difficult for the body to use glucose for energy. In this situation, fat becomes the energy source, which causes a dangerous build-up of ketones in the body, leading to ketoacidosis. The sodium-glucose cotransporter 2 (SGLT2) inhibitors (canagliflozin, dapagliflozin, and empagliflozin) are a new class of hypoglycemic medications (for patients with type 2 diabetes mellitus) that have been associated with an atypical presentation of DKA. Read more ...
